AC Immune Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
122
- Stock Symbol
-
ACIU
- Investments
-
1
- Share Price
-
$1.94
- (As of Friday Closing)
AC Immune General Information
Description
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Contact Information
Website
www.acimmune.comCorporate Office
- EPFL Innovation Park
- Building B
- 1015 Lausanne
- Switzerland
Corporate Office
- EPFL Innovation Park
- Building B
- 1015 Lausanne
- Switzerland
AC Immune Stock Performance
As of 20-Nov-2026, AC Immune’s stock price is $1.94. Its current market cap is $194M with 99M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.94 | $2.13 | $1.93 - $3.90 | $194M | 99M | 203K | -$0.44 |
AC Immune Financials Summary
As of 30-Sep-2026, AC Immune has a trailing 12-month revenue of $24.9M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 172,297 | 185,710 | 83,127 | 409,265 |
| Revenue | 24,870 | 4,299 | 31,015 | 16,465 |
| EBITDA | (83,765) | (58,845) | (58,822) | |
| Net Income | (45,250) | (84,763) | (57,826) | (60,331) |
| Total Assets | 166,852 | 194,781 | 255,568 | 217,651 |
| Total Debt | 4,671 | 5,734 | 6,006 | 4,163 |
AC Immune Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AC Immune Comparisons
Industry
Financing
Details
AC Immune Competitors (66)
One of AC Immune’s 66 competitors is Beam Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Beam Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Editas Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Alzinova | Corporation | Gothenburg, Sweden | ||||
| Denali Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ |
AC Immune Patents
AC Immune Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4834917-A1 | Targeting peptides, aav variants and uses thereof | Pending | 02-May-2025 | ||
| WO-2026229619-A2 | Targeting peptides, aav variants and uses thereof | Pending | 02-May-2025 | ||
| WO-2026209986-A1 | Fused tricyclic heterocycles having activity in preventing or decreasing tau aggregates | Pending | 03-Apr-2025 | ||
| WO-2026190322-A1 | Asc binding molecules for therapy and diagnosis | Pending | 13-Mar-2025 | ||
| WO-2026185478-A1 | Pyrazolo-pyrido-oxazine derivatives for the treatment of abnormalities associated with tau protein aggregates | Pending | 07-Mar-2025 | A61P25/28 |
AC Immune Signals
AC Immune Investments (1)
AC Immune’s most recent deal was a Corporate Asset Purchase with Affiris (Vaccine Candidate PD01) for . The deal was made on 27-Jul-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Affiris (Vaccine Candidate PD01) | 27-Jul-2021 | Corporate Asset Purchase | Buildings and Property |
AC Immune ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
AC Immune FAQs
-
When was AC Immune founded?
AC Immune was founded in 2003.
-
Where is AC Immune headquartered?
AC Immune is headquartered in Lausanne, Switzerland.
-
What is the size of AC Immune?
AC Immune has 122 total employees.
-
What industry is AC Immune in?
AC Immune’s primary industry is Drug Discovery.
-
Is AC Immune a private or public company?
AC Immune is a Public company.
-
What is AC Immune’s stock symbol?
The ticker symbol for AC Immune is ACIU.
-
What is the current stock price of AC Immune?
As of 20-Nov-2026 the stock price of AC Immune is $1.94.
-
What is the current market cap of AC Immune?
The current market capitalization of AC Immune is $194M.
-
What is AC Immune’s current revenue?
The trailing twelve month revenue for AC Immune is $24.9M.
-
Who are AC Immune’s competitors?
Beam Therapeutics, Editas Medicine, Alzinova, Denali Therapeutics, and Lisata Therapeutics are some of the 66 competitors of AC Immune.
-
What is AC Immune’s annual earnings per share (EPS)?
AC Immune’s EPS for 12 months was -$0.44.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process